CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS

The aim of the study was to conduct a pharmacoeconomic evaluation of the atezolizumab, vemurofenib and cobimetinib (ATZ+VM+COB) combination and the nivolumab and ipilimumab (NIVO+IPI) combination for the treatment of BRAF-confirmed metastatic melanoma in adult patients.Materials and methods. With th...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova
Fformat:	Artigo
Iaith:	Russo
Cyhoeddwyd:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2022-07-01
Cyfres:	Фармация и фармакология (Пятигорск)
Pynciau:	metastatic melanoma braf mutations melanoma treatment “cost-effectiveness” analysis “budget impact” analysis atezolizumab vemurafenib cobimetinib
Mynediad Ar-lein:	https://www.pharmpharm.ru/jour/article/view/1120
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!